CIS3 Antibody

What is CIS3/SOCS-3 and what is its primary role in cytokine signaling?

CIS3/SOCS-3 (also known as SSI-3) belongs to the CIS family of proteins that function as key negative regulators of cytokine signal transduction. CIS3 specifically inhibits the JAK/STAT pathway and acts as a negative regulator of fetal liver erythropoiesis . The protein contains an SH2 domain that enables its interaction with phosphorylated tyrosine residues on activated cytokine receptors and associated JAK kinases.

At the molecular level, CIS3 exerts its inhibitory effects by:

• Binding directly to the erythropoietin receptor (EPOR) and JAK2

• Inhibiting EPO-dependent proliferation and STAT5 activation

• Suppressing tyrosine phosphorylation of STAT proteins

• Potentially functioning as a substrate-recognition component in E3 ubiquitin-protein ligase complexes that mediate proteasomal degradation

This negative feedback mechanism serves as a critical regulatory control point for cytokine signaling, particularly for cytokines that signal through the JAK-STAT5 pathway including erythropoietin, prolactin, and interleukin-3 .

What applications are most appropriate for CIS3 antibodies in experimental research?

CIS3 antibodies can be utilized in multiple experimental approaches, with Western blotting (WB) and immunohistochemistry (IHC) being the most validated applications . When selecting a CIS3 antibody for your research, consider the following application-specific recommendations:

Western Blotting (WB):

• Ideal for quantifying total CIS3 protein levels across different experimental conditions

• Allows for detection of post-translational modifications with phospho-specific antibodies

• Effective for studying temporal changes in CIS3 expression following cytokine stimulation

Immunohistochemistry (IHC):

• Enables visualization of CIS3 expression patterns in tissue sections

• Valuable for comparing normal versus pathological samples

• Useful for co-localization studies with other signaling proteins

While not explicitly validated in the search results, other potential applications based on similar antibodies include:

• Immunoprecipitation for studying protein-protein interactions

• Flow cytometry for analyzing CIS3 in specific cell populations

• ChIP assays for examining STAT-binding to CIS3 promoter regions

When designing experiments, it's important to note that CIS3 antibodies are typically validated with human, mouse, and rat samples, with confirmed cross-reactivity for mouse but variable testing for rat samples .

What are the recommended protocols for validating CIS3 antibody specificity?

Validating antibody specificity is crucial for ensuring reliable experimental results. For CIS3 antibodies, implement the following validation approaches:

• Peptide Competition Assay:

  • Pre-incubate CIS3 antibody with the immunizing peptide (synthetic peptide from C-terminal part of Human CIS3/SOCS-3)

  • Run parallel Western blots with blocked and unblocked antibody

  • Disappearance of bands in the blocked sample confirms specificity

• Knockout/Knockdown Controls:

  • Compare signal between wild-type samples and CIS3/SOCS-3 knockout or knockdown samples

  • Signal should be absent or significantly reduced in knockout/knockdown samples

• Molecular Weight Verification:

  • Confirm that detected bands align with expected molecular weight

  • Look for the presence of expected post-translational modifications

• Cross-Species Reactivity Testing:

  • Test antibody against samples from multiple species (human, mouse, rat)

  • Note that while sequence homology is high across these species, validation testing may vary

• Positive Control Samples:

  • Use cells/tissues with known CIS3 expression (e.g., cytokine-stimulated cells)

  • Include samples from different species if cross-reactivity is claimed

Document all validation steps thoroughly in your methods section to support data reproducibility and reliability.

How can CIS3 antibodies be optimally used to study JAK/STAT pathway regulation in various experimental models?

CIS3/SOCS-3 plays a critical role in regulating JAK/STAT signaling across multiple cellular contexts. Advanced experimental designs utilizing CIS3 antibodies can reveal nuanced aspects of this regulation:

Time-course Analysis:

• Stimulate cells with relevant cytokines (EPO, IL-3, etc.)

• Collect samples at multiple timepoints (0, 15, 30, 60, 120, 240 minutes)

• Perform Western blotting for phosphorylated JAK2, STAT5, and CIS3

• This approach reveals the temporal relationship between pathway activation and negative feedback induction

Cell-type Specific Regulation:

• Compare CIS3 induction patterns across different cell types (erythroid progenitors, immune cells, etc.)

• Correlate CIS3 expression with downstream functional outcomes

• Consider single-cell approaches to capture heterogeneity within populations

Stimulus-specific Effects:

• Compare CIS3 induction following various cytokine stimuli (EPO, IL-3, IFN-γ)

• Analyze differences in the kinetics and magnitude of CIS3 upregulation

• Correlate with differential effects on JAK/STAT signaling components

For interferon-related studies, it's noteworthy that while CIS3 regulates EPO signaling, JAB/SOCS-1 has been implicated more specifically in interferon-gamma responses. This suggests distinct roles for different SOCS family members in cytokine specificity . When designing experiments to study these differential effects, consider using antibodies against multiple SOCS family members simultaneously.

What methodological approaches can improve CIS3 antibody performance in challenging experimental conditions?

Advanced researchers often encounter technical challenges when working with CIS3 antibodies in complex experimental systems. The following methodological refinements can help overcome these limitations:

Sample Preparation Optimization:

• For cell lysates: Use phosphatase inhibitors to preserve phosphorylation states

• For tissue samples: Optimize fixation time (typically 24 hours in 10% neutral buffered formalin)

• For all samples: Include protease inhibitors to prevent degradation of CIS3 during processing

Signal Enhancement Strategies:

• Implement tyramide signal amplification for low-abundance detection

• Use biotin-streptavidin systems for IHC applications

• Consider proximity ligation assays for detecting CIS3 interactions with binding partners

Antibody Format Selection:

• Lyophilized antibody formats provide longer shelf-life for intermittent use

• For quantitative applications, consider calibrating with recombinant standards

• For multiplex applications, select antibodies raised in different host species

Buffer Optimization:

• Standard formulation: 1% BSA in PBS containing 0.05% NaN3

• For difficult tissues: Consider specialized retrieval buffers (citrate vs. EDTA-based)

• For co-IP applications: Test different lysis buffers to preserve protein interactions

When working with phospho-specific antibodies against components of the CIS3 pathway, special care must be taken to rapidly extract and process samples to preserve phosphorylation states that may be transient following cytokine stimulation.

How do computational approaches contribute to CIS3 antibody design and application optimization?

Recent advances in computational methods have significantly enhanced antibody design and optimization strategies. For CIS3 research, several computational approaches offer valuable benefits:

Deep Learning for Antibody Design:

• Machine learning models can predict the effects of mutations on antibody properties

• Multi-objective linear programming with diversity constraints helps generate diverse, high-performing antibody libraries

• These approaches enable "cold-start" antibody design without requiring iterative wet lab feedback

Structure-Based Optimization:

• In silico deep mutational scanning provides comprehensive mutation effect predictions

• Integration of sequence and structure-based machine learning models improves antibody performance predictions

• Computational methods can identify mutations that enhance specificity for CIS3 over other SOCS family members

Experimental Design Optimization:

• Computational approaches can determine optimal experimental conditions

• Models can predict antibody behavior across different buffer conditions and applications

• Statistical methods help determine minimum sample sizes for reliable detection

The integration of computational and experimental approaches represents a powerful strategy for developing next-generation CIS3 antibodies with enhanced specificity, affinity, and versatility. As described in recent research, advanced computational methods can generate antibody libraries that balance extrinsic fitness (binding quality) with intrinsic fitness (stability, developability) .

What are the key considerations for using CIS3 antibodies to investigate cross-talk between cytokine signaling pathways?

Cytokine signaling networks involve complex cross-talk mechanisms, with CIS3/SOCS-3 serving as an important regulatory node. When designing experiments to investigate these interactions, consider:

Multiplex Detection Strategies:

• Use phospho-flow cytometry with CIS3 antibodies alongside phospho-JAK and phospho-STAT antibodies

• Implement multiplexed Western blotting with differently labeled secondary antibodies

• Design co-immunoprecipitation experiments to capture CIS3 complexes

Pathway Interference Analysis:

• Pre-treat cells with one cytokine to induce CIS3, then challenge with a second cytokine

• Measure effects on JAK/STAT activation in the second pathway

• Compare results across multiple cell types to identify context-specific regulation

Temporal Dynamics Consideration:

• Design experiments that capture both rapid (minutes) and delayed (hours) responses

• Implement live-cell imaging with fluorescently tagged CIS3 constructs

• Compare kinetics of different pathway components to establish causality

It's important to note that CIS3 functions within a complex network of regulators. While CIS3 specifically inhibits STAT5 transactivation through suppression of tyrosine phosphorylation , JAB/SOCS-1 has been shown to inhibit JAK1 and JAK2 activation in response to IFN-gamma . These differential effects highlight the need for careful experimental design when studying pathway cross-talk.

How can researchers effectively apply CIS3 antibodies in studying disease-relevant mechanisms?

CIS3/SOCS-3 dysregulation has been implicated in various pathological conditions. When designing disease-focused studies using CIS3 antibodies, consider these approaches:

Comparative Expression Analysis:

• Compare CIS3 levels between healthy and pathological tissues

• Correlate expression with disease severity markers

• Examine cellular localization changes in disease states

Therapeutic Response Monitoring:

• Measure CIS3 expression before and after therapeutic interventions

• Use as a biomarker for cytokine signaling normalization

• Correlate changes with clinical outcomes

Genetic Variant Impact:

• Compare antibody recognition of wild-type versus variant CIS3 proteins

• Assess functional consequences of disease-associated mutations

• Develop variant-specific antibodies for personalized research

While not directly related to CIS3/SOCS-3, the CIS43LS monoclonal antibody research for malaria prevention demonstrates how antibody engineering approaches (such as the LS mutation to extend half-life) can dramatically improve therapeutic potential . Similar engineering principles could potentially be applied to develop tools for studying CIS3 in disease contexts.

Common Applications and Validation Status for CIS3 Antibodies

*Cross-reactivity with rat confirmed for some antibodies but requires validation for each specific antibody

Comparison of CIS Family Proteins and Their Functional Roles

This comparison highlights the specific role of CIS3/SOCS-3 within the broader context of cytokine signaling regulation .